At a glance
- Originator nPharmakon LLC
- Class Amines; Anti-inflammatories; Benzyl compounds; Pyrazoles; Skin disorder therapies; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperpigmentation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Hyperpigmentation in USA (Topical, Gel)
- 01 Jul 2015 NPH 29 is available for licensing as of 07 Jul 2015. http://www.npharmakon.com/content/pipeline.html
- 01 Jul 2015 Efficacy and adverse events data from a clinical study in Hyperpigmentation released by nPharmakon